Treatment-Induced Autophagy Associated with Tumor Dormancy and Relapse
Technical Report,01 Jul 2016,30 Jun 2017
Virginia Commonwealth University Richmond United States
Pagination or Media Count:
Despite advances in cancer therapeutics over recent decades, developing effective strategies for the treatment of triple negative breast cancer TNBC continues to represent a significant challenge. Cytotoxic chemotherapies that often include doxorubicin Adriamycin remain the standard of care in breast cancer while generally successful, patients frequently relapse with therapy resistant disease. Immunotherapy has emerged as a treatment modality with great promise, but has seen limited success in breast cancer therapy due, in large part,to the low immunogenicity of breast cancer cells. In view of the fact that doxorubicin has been shown to improve tumor immunogenicity by promoting the secretion of damage-associated molecular pattern DAMP molecules and immunogenic cell death ICD, our recent goals were to enhance sensitivity to chemotherapy by both cell autonomous and cell non-autonomous strategies.
- Medicine and Medical Research